title: Evaluation of quantitative EEG by classification and regression trees to characterize responders to antidepressant and placebo treatment.
abstract: The study objective was to evaluate the usefulness of Classification and Regression Trees (CART), to classify clinical responders to antidepressant and placebo treatment, utilizing symptom severity and quantitative EEG (QEEG) data. Patients included 51 adults with unipolar depression who completed treatment trials using either fluoxetine, venlafaxine or placebo. Hamilton Depression Rating Scale (HAM-D) and single electrodes data were recorded at baseline, 2, 7, 14, 28 and 56 days. Patients were classified as medication and placebo responders or non-responders. CART analysis of HAM-D scores showed that patients with HAM-D scores lower than 13 by day 7 were more likely to be treatment responders to fluoxetine or venlafaxine compared to non-responders (p=0.001). Youden's index γ revealed that CART models using QEEG measures were more accurate than HAM-D-based models. For patients given fluoxetine, patients with a decrease at day 2 in θ cordance at AF2 were classified by CART as treatment responders (p=0.02). For those receiving venlafaxine, CART identified a decrease in δ absolute power at day 7 at the PO2 region as characterizing treatment responders (p=0.01). Using all patients receiving medication, CART identified a decrease in δ absolute power at day 2 in the FP1 region as characteristic of nonresponse to medication (p=0.003). Optimal trees from the QEEG CART analysis primarily utilized cordance values, but also incorporated some δ absolute power values. The results of our study suggest that CART may be a useful method for identifying potential outcome predictors in the treatment of major depression.
authors: Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
authors: M
authors: M
authors: Rabinoff
authors: C M R
authors: CM
authors: Kitchen
authors: I A
authors: IA
authors: Cook
authors: A F
authors: AF
authors: Leuchter
references: Biol Psychiatry. 1997 Sep 1;42(5):317-23
references: 9276071
references: Eur Arch Psychiatry Neurol Sci. 1985;234(6):417-22
references: 4029226
references: Depress Anxiety. 1996-1997;4(6):257-67
references: 9166653
references: Semin Clin Neuropsychiatry. 2001 Apr;6(2):113-20
references: 11296311
references: Eur Arch Psychiatry Neurol Sci. 1989;238(5-6):231-9
references: 2548868
references: Electroencephalogr Clin Neurophysiol. 1998 Dec;107(6):408-14
references: 9922086
references: Arch Gen Psychiatry. 2001 Jul;58(7):631-40
references: 11448368
references: Acta Psychiatr Scand. 1975 Mar;51(3):161-70
references: 1136841
references: Stat Med. 1996 May 30;15(10):969-86
references: 8783436
references: Psychiatry Res. 1999 Mar 22;85(3):263-73
references: 10333379
references: J Clin Psychiatry. 1997;58 Suppl 16:22-31
references: 9430506
references: J Psychiatr Res. 2000 Jan-Feb;34(1):3-10
references: 10696827
references: Am J Psychiatry. 1995 Oct;152(10):1500-3
references: 7573590
references: Dev Neurosci. 2002;24(4):255-61
references: 12457063
references: J Psychiatr Res. 2005 Sep;39(5):461-6
references: 15992554
references: J Psychiatry Neurosci. 1995 Jan;20(1):25-32
references: 7865498
references: Neuropsychopharmacology. 2002 Jul;27(1):120-31
references: 12062912
references: Psychiatry Res. 1999 Apr 26;90(2):125-40
references: 10482384
references: Am J Psychiatry. 1996 Feb;153(2):151-62
references: 8561194
references: Am J Psychiatry. 2002 Jan;159(1):122-9
references: 11772700